Renal safety of zoledronic acid administration beyond 24 months in breast cancer patients with bone metastases

Medical Oncology
Murat DincerIbrahim Gullu

Abstract

Zoledronic acid (ZA) delays the onset or reduces the incidence of skeletal complications in breast cancer patients with bone metastases. However, there are few data on the long-term renal safety of ZA. We retrospectively evaluated 43 breast cancer patients with bone metastases who received ZA more than 24 months. The following parameters measured prior to first ZA use and after the last dose of ZA administration were compared: serum creatinine (SCr), blood urea nitrogen (BUN), alkaline phosphatase (ALP), calcium (Ca), and phosphorous (P). Forty-three breast cancer patients with documented bone metastases were evaluated. Median age at the start of treatment was 53 years (range 37-77). Median overall duration of ZA administration was 36 months (25-62). There were no statistically significant differences in the pre- and post-treatment levels of SCr, BUN, Ca and P. However, ALP levels after long-term ZA administration were decreased significantly (P<0.05). More than 24 months of ZA administration did not adversely affect the renal function. ZA can be used safely in breast cancer patients with bone metastases beyond 2 years.

References

Jan 1, 1976·Nephron·D W Cockcroft, M H Gault
Feb 26, 1983·Lancet·H M BounameauxF Chatelanat
Dec 20, 1999·Drug Safety : an International Journal of Medical Toxicology and Drug Experience·N ZojerM Pecherstorfer
May 25, 2001·Journal of the American Society of Nephrology : JASN·Glen S MarkowitzVivette D D'Agati
Jul 17, 2001·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·S M AliA Lipton
Jun 6, 2003·Kidney International·Glen S MarkowitzVivette D D'Agati
Sep 26, 2003·The New England Journal of Medicine·Bernard S Chang, Daniel H Lowenstein
Oct 24, 2003·The New England Journal of Medicine·Jennie T ChangJulie Beitz
Feb 19, 2005·Current Treatment Options in Oncology·Allan Lipton
Jul 22, 2005·The Cochrane Database of Systematic Reviews·N PavlakisM Stockler
Mar 21, 2006·Annals of Oncology : Official Journal of the European Society for Medical Oncology·T Tanvetyanon, P J Stiff
Nov 4, 2006·Annals of Oncology : Official Journal of the European Society for Medical Oncology·D Aguiar BujandaJ Aguiar Morales
May 4, 2007·Clinical Nephrology·N GokdenJ Kumar

❮ Previous
Next ❯

Citations

Aug 21, 2013·Case Reports in Oncological Medicine·Ali Murat TatlıHasan Şenol Coşkun
Jun 15, 2020·Supportive Care in Cancer : Official Journal of the Multinational Association of Supportive Care in Cancer·Terry L NgMark J Clemons

❮ Previous
Next ❯

Related Concepts

Related Feeds

Breast Invasive Carcinoma

Invasive breast cancers indicate a spread into breast tissues and lymph nodes. Here are the latest discoveries pertaining to breast invasive carcinomas.

Breast Invasive Carcinoma (Keystone)

Invasive breast cancers indicate a spread into breast tissues and lymph nodes. Here are the latest discoveries pertaining to breast invasive carcinomas.

Related Papers

Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
Alison T StopeckAda Braun
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
Catherine Van PoznakAmerican Society of Clinical Oncology
Annals of Oncology : Official Journal of the European Society for Medical Oncology
M AaproB Thürlimann
Annals of Oncology : Official Journal of the European Society for Medical Oncology
Evangelos TerposEuropean Myeloma Network
© 2021 Meta ULC. All rights reserved